Company intelligence / Profile preview

Eno Pharmaceutical

Beijing, China

Ownership: Private
Development stage: Other

Overview

Eno Pharmaceutical is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal disorders. The company's lead candidate is a potassium-competitive acid blocker (P-CAB) designed to provide faster and more sustained acid suppression compared to traditional proton pump inhibitors. Eno Pharmaceutical is currently advancing its primary asset through late-stage clinical trials for indications such as erosive esophagitis and peptic ulcers. The company aims to address unmet medical needs in the acid-related disease market by offering improved safety and efficacy profiles.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Eno Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eno Pharmaceutical.

Explore the full profile